HOOKIPA Pharma Inc stock (US43906K1007): Delisted to OTC amid price volatility

HOOKIPA Pharma Inc (HOOK) was delisted to OTC markets, following a sharp -6.88% drop to $0.97 on July 22, 2025. Technical forecasts point to further weakness.

HOOKIPA Pharma Inc shares have faced significant turbulence, including a delisting to over-the-counter (OTC) trading as noted in recent corporate action updates. On July 22, 2025, the stock fell 6.88% from $1.04 to $0.97 on Nasdaq, with intraday volatility reaching 11.83%, according to stockinvest.us as of May 12, 2026. This move underscores ongoing challenges for the biopharma firm.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hookipa Pharma Inc
• Sector/industry: Biotechnology
• Headquarters/country: Austria
• Core markets: US, Europe
• Home exchange/listing venue: Nasdaq (HOOK), now OTC
• Trading currency: USD

HOOKIPA Pharma Inc: core business model

HOOKIPA Pharma Inc develops immunotherapies using its proprietary arenavirus platform for infectious diseases and cancers. The company focuses on arenaviral vectors to induce potent T cell responses, targeting HPV-associated cancers and other indications. Headquartered in Vienna, Austria, with US operations, it aims to create best-in-class treatments through partnerships like those with Roche and Gilead.

Main revenue and product drivers for HOOKIPA Pharma Inc

Key drivers include HB-201, an HPV16-positive cancer therapy in phase 2 trials, and collaborations providing milestone payments and royalties. Revenue stems from research funding, grants, and potential commercialization, with US investors tracking progress amid biotech sector dynamics.

Industry trends and competitive position

The biotech sector sees rising focus on immunotherapy, with HOOKIPA's vector tech differentiating it from CAR-T and checkpoint inhibitors. US market exposure via Nasdaq (pre-delisting) and trials positions it for investors eyeing oncology innovation.

Conclusion

The delisting to OTC and recent price drop highlight volatility for HOOKIPA Pharma Inc, driven by clinical and market factors. Investors monitor pipeline advancements and partnerships for potential recovery. US exposure remains via biotech relevance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.